BACKGROUND/AIM: The FOXC2 transcription factor promotes the progression of several cancer types, but has not been investigated in the context of melanoma cells. To study FOXC2's influence on melanoma progression, we generated a FOXC2-deficient murine melanoma cell line and evaluated The Cancer Genome Atlas (TCGA) patient datasets. MATERIALS AND METHODS: We compared tumor growth kinetics and RNA-seq/qRT-PCR gene expression profiles from wild-type versus FOXC2-deficient murine melanomas. We also performed Kaplan-Meier survival analysis of TCGA data to assess the influence of FOXC2 gene expression on melanoma patients' response to chemotherapy and immunotherapy. RESULTS: FOXC2 promotes melanoma progression and regulates the expression of genes associated with multiple oncogenic pathways, including the oxidative stress response, xenobiotic metabolism, and interferon responsiveness. FOXC2 expression in melanoma correlates negatively with patient response to chemotherapy and immunotherapy. CONCLUSION: FOXC2 drives a tumor-promoting gene expression program in melanoma and is a prognostic indicator of patient response to multiple cancer therapies. Copyright
BACKGROUND/AIM: The FOXC2 transcription factor promotes the progression of several cancer types, but has not been investigated in the context of melanoma cells. To study FOXC2's influence on melanoma progression, we generated a FOXC2-deficient murine melanoma cell line and evaluated The Cancer Genome Atlas (TCGA) patient datasets. MATERIALS AND METHODS: We compared tumor growth kinetics and RNA-seq/qRT-PCR gene expression profiles from wild-type versus FOXC2-deficient murine melanomas. We also performed Kaplan-Meier survival analysis of TCGA data to assess the influence of FOXC2 gene expression on melanomapatients' response to chemotherapy and immunotherapy. RESULTS:FOXC2 promotes melanoma progression and regulates the expression of genes associated with multiple oncogenic pathways, including the oxidative stress response, xenobiotic metabolism, and interferon responsiveness. FOXC2 expression in melanoma correlates negatively with patient response to chemotherapy and immunotherapy. CONCLUSION:FOXC2 drives a tumor-promoting gene expression program in melanoma and is a prognostic indicator of patient response to multiple cancer therapies. Copyright
Authors: C Isogai; W E Laug; H Shimada; P J Declerck; M F Stins; D L Durden; A Erdreich-Epstein; Y A DeClerck Journal: Cancer Res Date: 2001-07-15 Impact factor: 12.701
Authors: Ahmad Najem; Mohammad Krayem; Anne Perdrix; Joseph Kerger; Ahmad Awada; Fabrice Journe; Ghanem Ghanem Journal: Anticancer Res Date: 2017-11 Impact factor: 2.480
Authors: Sendurai A Mani; Jing Yang; Mary Brooks; Gunda Schwaninger; Alicia Zhou; Naoyuki Miura; Jeffery L Kutok; Kimberly Hartwell; Andrea L Richardson; Robert A Weinberg Journal: Proc Natl Acad Sci U S A Date: 2007-05-30 Impact factor: 11.205
Authors: Maria Sol Recouvreux; Jiangyong Miao; Maricel C Gozo; Jingni Wu; Ann E Walts; Beth Y Karlan; Sandra Orsulic Journal: Cancers (Basel) Date: 2022-10-04 Impact factor: 6.575